SCHEMBL3428705

SCHEMBL3428705

COc1ccc(NC(=O)c2nn(Cc3ccc(S(C)(=O)=O)cc3)c3ccccc23)cc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 5/20 0.60
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
KDM4E B2RXH2 1/20 0.49
CNR1 P21554 1/20 0.47
CNR2 P34972 1/20 0.47
ROCK1 Q13464 1/20 0.47
MAPT P10636 2/20 0.47
POLB P06746 1/20 0.47
AKR1C3 P42330 2/20 0.47
ELANE P08246 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MCL1 Q07820 1/20 0.46
HIF1A Q16665 1/20 0.45
CDK2 P24941 1/20 0.45
FLT3 P36888 1/20 0.45
IDH1 O75874 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3755332 0.93 KDM4E (0.54) PTGER4MEN1KMT2AKDM4ECNR1
SCHEMBL3428395 0.90 PTGER4 (0.54) PTGER4MEN1KMT2AKDM4ECNR1
SCHEMBL3430632 0.90 PTGER4 (0.56) PTGER4MEN1KMT2AMAPTAKR1C3
SCHEMBL3428006 0.89 PTGER4 (0.57) PTGER4MEN1KMT2AKDM4ECNR1
SCHEMBL3428570 0.89 KDM4E (0.51) PTGER4MEN1KMT2AKDM4ECNR1
SCHEMBL3411563 0.89 ELANE (0.51) PTGER4MEN1KMT2AKDM4ECNR1
SCHEMBL3430198 0.89 KDM4E (0.51) PTGER4MEN1KMT2AKDM4ECNR1
SCHEMBL3429031 0.89 MEN1 (0.51) PTGER4MEN1KMT2AKDM4ECNR1
SCHEMBL3428221 0.89 PTGER4 (0.61) PTGER4MEN1KMT2AKDM4ECNR1
SCHEMBL3428417 0.88 PTGER4 (0.57) PTGER4MEN1KMT2AKDM4ECNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP claimed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US claimed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO claimed
EP-2257340-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-12-08 EP disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
WO-2009121623-A2 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY CPT1B, SMN1; SMN2, GYS1 PTGER4 3500/4885MEN1 3958/4885KMT2A 2516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.